Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Sales (2023 - 2025)

Historic Return on Sales for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 3.49%.

  • bioAffinity Technologies' Return on Sales fell 26400.0% to 3.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.17%, marking a year-over-year decrease of 12700.0%. This contributed to the annual value of 0.97% for FY2024, which is 21700.0% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Return on Sales stood at 3.49%, which was down 26400.0% from 3.2% recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Return on Sales peaked at 0.82% during Q1 2024, and registered a low of 4277.79% during Q3 2022.
  • In the last 4 years, bioAffinity Technologies' Return on Sales had a median value of 3.35% in 2025 and averaged 488.01%.
  • Within the past 5 years, the most significant YoY rise in bioAffinity Technologies' Return on Sales was 42701100bps (2023), while the steepest drop was -207400bps (2023).
  • Over the past 4 years, bioAffinity Technologies' Return on Sales (Quarter) stood at 713.8% in 2022, then soared by 100bps to 1.07% in 2023, then dropped by -25bps to 1.34% in 2024, then tumbled by -160bps to 3.49% in 2025.
  • Its last three reported values are 3.49% in Q3 2025, 3.2% for Q2 2025, and 1.44% during Q1 2025.